Oasmia plans to seek partnerships for XR17 excipient technology

Swedish firm Oasmia Pharmaceutical (STO: OSM) says it intends to identify international marketing, distribution and development partners to facilitate entry into a number of key markets following anticipated but pending approval from regulatory bodies such as the European Medicines Agency, the Food and Drug Administration in the USA, and other regions throughout the world.

Oasmia has already initiated this process by hosting introductory and in-depth conversations with multiple potential partners. The company views this step as a crucial objective following its recent submissions, and its anticipated submission to the FDA in the end of 2016/2017.

Oasmia believes it has bolstered the process with both entities following the recently released Overall Survival (OS) Phase III data results that it plans to add to and include in both submissions. Further, the company has disclosed that it has reviewed term sheets for the licensing of its XR17 excipient technology, an innovative drug delivery program that the company believes possesses significant potential across many pharmaceutical indications beyond the cytostatic drug market.